Non-invasive Assessment of Inflammatory Markers MIP-1 Alpha and IL-6 in Saliva of Post Myocardial Infarction and Stage 4 Periodontitis Patients

NCT ID: NCT05314192

Last Updated: 2022-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2021-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Periodontitis is an immunoinflammatory disease caused by microorganisms leading to sequential loss of the supporting structures of periodontium, resulting in periodontal pocket formation, gingival recession eventually leading to tooth loss.\[1\] A bacterial plaque is formed during the destructive changes of the periodontium which initiates a host of inflammatory and immune responses.\[2\] These inflammatory responses may also cause an increase in inflammatory activities in atherosclerotic lesions in the coronary arteries resulting in the increased risk of cardiovascular events like myocardial infarction.\[3\] Myocardial infarction (MI) is a cardiovascular condition that occurs when there is deprivation of oxygen in the heart muscle is due to the sudden interruption of the blood supply resulting from the coronary artery blockage by a plaque causing myocardial ischemia and cell death. Inflammation is pivotal in the initiation and progression of atherosclerosis. Various cytokines and chemokines are released during inflammation.\[4\] These inflammatory markers may have diagnostic potential for the detection of various inflammatory diseases.\[5\] Macrophages secrete macrophage inflammatory protein-1 alpha (MIP-1 alpha) which recruits inflammatory cells, inhibits stem cells, and activates bone resorption cells.\[6\] Interleukin-6 (IL-6) is produced in response to tissue injury and infection and contributes to the differentiation of B cells, the proliferation of T cells, and bone resorption.\[7\] The levels of these inflammatory markers are seen to be increased in inflammatory conditions, which include myocardial infarction and stage 4 periodontitis. Therefore, this study aims to assess the levels of these inflammatory markers in patients with myocardial infarction and periodontitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a cross-sectional study involving the patients of the department of periodontics and department of cardiology.

Patients included in the study were categorized into four groups: (1) group 1-healthy subjects, (2) group 2-stage 4 periodontitis patients, (3) group 3- post-MI patients with stage 4 periodontitis, (4) group 4- post-MI patients without periodontitis.

The severity of the periodontitis was assessed by a periodontist. The diagnosis of acute MI was made by the cardiologists. Oral health assessment in acute MI patients was done at the subjects' bedside after stabilization of the patient, so as not to interfere with the ongoing medical treatment. Subjects' identification was kept confidential.

All samples were collected from patients admitted within 48 hours of their cardiac event. Patients were diagnosed as acute ST-elevation myocardial infarction (STEMI) based on the elevation of ST segments on the electrocardiogram(ECG) by 0.1mV in contiguous leads in patients with signs and symptoms of myocardial ischemia and/ or development of new left bundle branch block, along with increased cardiac biomarkers. Non-ST-elevation myocardial infarction (NSTEMI) was diagnosed in patients with signs and symptoms of myocardial ischemia and depression in ST-segment on the ECG or new Q wave pathology along with elevation of cardiac biomarkers.\[8\] Stage four periodontitis was diagnosed using the World Workshop 2017 classification.\[9\] Subjects who had undergone oral prophylaxis or periodontal surgery in the past 6 months were not included in the study. Smokers, pregnant women, lactating mothers, and those on medication (anti-microbial, non-steroidal anti-inflammatory drugs) in the past 3 months as well as those with other chronic systemic diseases were excluded from the study. These were all excluded as each would affect the levels of biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Periodontal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy

Healthy cohorts with no underlying systemic or periodontal disease

salivary test

Intervention Type DIAGNOSTIC_TEST

saliva was assessed for MIP-1 alpha

salivary test

Intervention Type DIAGNOSTIC_TEST

saliva was assessed for IL-6

stage 2 periodontitis

patients with periodontitis but no underlying systemic periodontal disease

salivary test

Intervention Type DIAGNOSTIC_TEST

saliva was assessed for MIP-1 alpha

salivary test

Intervention Type DIAGNOSTIC_TEST

saliva was assessed for IL-6

MI patients with stage 4 periodontitis

patients who had MI and having stage 4 periodontitis patients

salivary test

Intervention Type DIAGNOSTIC_TEST

saliva was assessed for MIP-1 alpha

salivary test

Intervention Type DIAGNOSTIC_TEST

saliva was assessed for IL-6

MI patients without periodontitis

patients who had MI without periodontitis

salivary test

Intervention Type DIAGNOSTIC_TEST

saliva was assessed for MIP-1 alpha

salivary test

Intervention Type DIAGNOSTIC_TEST

saliva was assessed for IL-6

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

salivary test

saliva was assessed for MIP-1 alpha

Intervention Type DIAGNOSTIC_TEST

salivary test

saliva was assessed for IL-6

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* subjects who had MI
* who had stage 4 periodontal disease

Exclusion Criteria

* subjects who did not have MI
* subjects who had systemic disease other than MI
* subjects who had medication in the past 3 months
* smokers
* pregnant and lactating women
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

A B Shetty Memorial Institute of Dental Science

OTHER

Sponsor Role collaborator

Ajman University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

sudhir rama varma

Clinical Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AB shetty Institute of dental sciences

Mangalore, , India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ABSM/EC/29/2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.